Aller au contenu principal
Accès ouvert déclaré 2026 article

Patient-reported quality of life after chemoradiotherapy in patients with non-metastatic anal squamous cell carcinoma: A cross-sectional cohort study

0Citations signalées, ce qui n’est pas une note de qualité
6Institutions déclarées
1Pays d’affiliation déclarés

Rattachement africain : nl. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

BACKGROUND AND PURPOSE: For most patients with non-metastatic anal squamous cell carcinoma (ASCC), chemoradiotherapy (CRT) is the standard treatment. Data on long-term health-related quality of life (HRQoL) following CRT are limited. This study evaluated HRQoL and functioning of patients with ASCC after CRT and compared outcomes with a normative population. MATERIALS AND METHODS: In this cross-sectional cohort study, patient-reported outcome measures (PROMs) from the Prospective Dutch ColoRectal Cancer (PLCRC) cohort were linked to clinical data from the Netherlands Cancer Registry. Patients with stage I-III ASCC diagnosed between 2016 and 2025 who completed the EORTC-QLQ-C30, EORTC-QLQ-CR29, Low Anterior Resection Syndrome (LARS) and/or Stoma Quality of Life (SQOLS) questionnaire ≥ 6 months after CRT were included. The C30 scores were compared to a sex-, age-, and comorbidity matched (1:3) Dutch normative population. RESULTS: A total of 72 patients were included (67% female; median age 65 years, 49% stage III). The median interval between end of CRT and C30 and CR29 questionnaire completion was 21.7 months. Compared with the normative population, patients reported lower overall HRQoL, lower functioning across all domains, and higher levels of fatigue and diarrhoea. Prominent CR29-reported symptoms included flatulence (mean 43.3), urinary frequency (mean 33.1), and embarrassment by defecation pattern (mean 31.8). Among patients without stoma, 62% (n = 32) reported major LARS. CONCLUSION: Patients with ASCC report reduced HRQoL after CRT compared to a normative population. These findings underscore the importance of post-treatment supportive care and insight into PROMs during routine follow-up may help tailor individualised guidance of patients.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Patient-reported quality of life after chemoradiotherapy in patients with non-metastatic anal squamous cell carcinoma: A cross-sectional cohort study
Date Crossref
01/09/2026
Éditeur
Elsevier BV
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Colorectal and Anal CarcinomasAnorectal Disease Treatments and OutcomesEsophageal Cancer Research and Treatment

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.